Advances in ophthalmology practice and research最新文献

英文中文

Reply to the letter to the editor regarding “Is relying on RNFL specific enough to identify any changes in the CNS?” 回复致编辑的信，内容涉及 "依靠 RNFL 的特异性是否足以识别中枢神经系统的任何变化？

Advances in ophthalmology practice and research

Pub Date : 2024-02-01 DOI: 10.1016/j.aopr.2024.01.003

Hanfei Wu, Haishuang Lin, Mengting Ruan, Huanjie Fang, Nannan Dong, Tiewei Wang, Feifei Yu, Jiawei Zhao

引用次数: 0

Recent progress of nanomedicine in managing dry eye disease 纳米医学在治疗干眼症方面的最新进展

Advances in ophthalmology practice and research

Pub Date : 2024-02-01 DOI: 10.1016/j.aopr.2024.01.008

Zeen Lv , Su Li , Guixiang Zeng , Ke Yao , Haijie Han

Background

Dry eye disease (DED) is a commonly reported ocular complaint that has garnered significant attention in recent research. The global occurrence of DED ranges from 5% to 50%, impacting a substantial proportion of individuals worldwide with increasing frequency. Although topical administration remains the mainstream drug delivery method for ocular diseases, it suffers from drawbacks such as low bioavailability, rapid drug metabolism, and frequent administration requirements. Fortunately, the advancements in nanomedicine offer effective solutions to address the aforementioned issues and provide significant assistance in the treatment of DED.

Main text

DED is considered a multifactorial disease of the ocular surface and tear film, in which the integrity of tear film function and structure plays a crucial role in maintaining the homeostasis of the ocular surface. The conventional treatment for DED involves the utilization of artificial tear products, cyclosporin, corticosteroids, mucin secretagogues, and nonsteroidal anti-inflammatory drugs. Furthermore, nanomedicine is presently a significant field of study, with numerous clinical trials underway for various nanotherapeutics including nanoemulsions, nanosuspensions, liposomes, and micelles. Notably, some of these innovative nanoformulations have already received FDA approval as novel remedies for DED, and the advancement of nanomedicine is poised to offer enhanced prospects to solve the shortcomings of existing treatments for DED partially.

Conclusions

This article provides an overview of the latest advancements in nanomedicine for DED treatment, while the field of DED treatment is expected to witness a remarkable breakthrough shortly with the development of nanomedicine, bringing promising prospects for patients worldwide suffering conditions.

背景干眼症（DED）是一种常见的眼部疾病，在最近的研究中备受关注。DED 的全球发病率从 5%到 50%不等，影响着全球很大一部分人，而且发病频率越来越高。虽然局部用药仍是眼部疾病的主流给药方法，但它存在生物利用度低、药物代谢快和给药要求频繁等缺点。正文DED被认为是眼表和泪膜的一种多因素疾病，其中泪膜功能和结构的完整性在维持眼表平衡方面起着至关重要的作用。DED 的传统治疗方法包括使用人工泪液产品、环孢素、皮质类固醇、粘蛋白促泌剂和非甾体抗炎药。此外，纳米医学目前也是一个重要的研究领域，各种纳米治疗药物（包括纳米乳剂、纳米悬浮剂、脂质体和胶束）的大量临床试验正在进行中。值得注意的是，其中一些创新型纳米制剂已获得美国食品及药物管理局（FDA）批准，可作为治疗 DED 的新型疗法，纳米医学的发展有望为部分解决现有 DED 治疗方法的不足之处提供更广阔的前景。结论本文概述了纳米医学在 DED 治疗方面的最新进展，随着纳米医学的发展，DED 治疗领域有望在短期内取得重大突破，为全球 DED 患者带来光明前景。

{"title":"Recent progress of nanomedicine in managing dry eye disease","authors":"Zeen Lv , Su Li , Guixiang Zeng , Ke Yao , Haijie Han","doi":"10.1016/j.aopr.2024.01.008","DOIUrl":"https://doi.org/10.1016/j.aopr.2024.01.008","url":null,"abstract":"<div><h3>Background</h3><p>Dry eye disease (DED) is a commonly reported ocular complaint that has garnered significant attention in recent research. The global occurrence of DED ranges from 5% to 50%, impacting a substantial proportion of individuals worldwide with increasing frequency. Although topical administration remains the mainstream drug delivery method for ocular diseases, it suffers from drawbacks such as low bioavailability, rapid drug metabolism, and frequent administration requirements. Fortunately, the advancements in nanomedicine offer effective solutions to address the aforementioned issues and provide significant assistance in the treatment of DED.</p></div><div><h3>Main text</h3><p>DED is considered a multifactorial disease of the ocular surface and tear film, in which the integrity of tear film function and structure plays a crucial role in maintaining the homeostasis of the ocular surface. The conventional treatment for DED involves the utilization of artificial tear products, cyclosporin, corticosteroids, mucin secretagogues, and nonsteroidal anti-inflammatory drugs. Furthermore, nanomedicine is presently a significant field of study, with numerous clinical trials underway for various nanotherapeutics including nanoemulsions, nanosuspensions, liposomes, and micelles. Notably, some of these innovative nanoformulations have already received FDA approval as novel remedies for DED, and the advancement of nanomedicine is poised to offer enhanced prospects to solve the shortcomings of existing treatments for DED partially.</p></div><div><h3>Conclusions</h3><p>This article provides an overview of the latest advancements in nanomedicine for DED treatment, while the field of DED treatment is expected to witness a remarkable breakthrough shortly with the development of nanomedicine, bringing promising prospects for patients worldwide suffering conditions.</p></div>","PeriodicalId":72103,"journal":{"name":"Advances in ophthalmology practice and research","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667376224000088/pdfft?md5=ebc5ca87a18661140e0772d47574d08c&pid=1-s2.0-S2667376224000088-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139709483","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Crossover to PDT after the unsuccessful micropulse laser treatment of central serous chorioretinopathy 微脉冲激光治疗中心性浆液性脉络膜视网膜病变失败后转用光导疗法

Advances in ophthalmology practice and research

Pub Date : 2024-02-01 DOI: 10.1016/j.aopr.2024.01.004

Maciej Gawęcki , Krzysztof Kiciński , Andrzej Grzybowski

Purpose

Subthreshold micropulse laser (SML) and photodynamic therapy (PDT) are among the most effective therapeutic modalities applied to central serous chorioretinopathy (CSCR). This study aimed to evaluate the efficacy and durability of PDT in CSCR cases unresponsive to at least two SML treatments.

Methods

The study included 26 consecutive eyes of 24 patients (21 males and three females) with chronic CSCR. In all cases, a lack of reduction in subretinal fluid (SRF) levels was noted after at least two consecutive SML sessions. The parameters of best corrected visual acuity (BCVA) and spectral domain optical coherence tomography (SD-OCT) were evaluated at baseline and 1, 3 and 12 months post-PDT.

Results

The mean duration of symptoms in the group was 53.81 ± 39.48 months, the mean age of the patients was 49.26 ± 12.91 years, and the mean subfoveal choroidal thickness (SFCT) was 572.11 ± 116.21 mm. Complete resorption of SRF was observed in 21 out of 26 eyes (80.77%) at 1 month and sustained in 18 cases (69.23%) at 12 months. At 12 months, in the sustained group, BCVA improved significantly from 0.39 ± 0.18 to 0.19 ± 0.2 logMAR (P = 0.01), central subfoveal thickness (CST) reduced from 316.44 ± 75.83 mm to 197.67 ± 22.99 mm (P < 0.0001), and SFCT reduced from 579.28 mm to 446.78 mm (P < 0.0001).

Conclusions

PDT provides the opportunity for the successful treatment of CSCR unresponsive to SML treatment. Improvements are possible even in cases with a long duration of symptoms and significant alterations in retinal morphology. Thus, PDT should be considered for patients with prominently increased choroidal thickness.

目的阈下微脉冲激光（SML）和光动力疗法（PDT）是治疗中心性浆液性脉络膜视网膜病变（CSCR）最有效的治疗方法之一。本研究旨在评估光动力疗法对至少两次 SML 治疗无效的 CSCR 病例的疗效和持久性。在所有病例中，经过至少两次连续的 SML 治疗后，视网膜下积液（SRF）水平均未下降。结果该组患者的平均病程为（53.81±39.48）个月，平均年龄为（49.26±12.91）岁，平均视网膜下脉络膜厚度（SFCT）为（572.11±116.21）毫米。26只眼睛中有21只（80.77%）在1个月时观察到SRF完全吸收，18只（69.23%）在12个月时观察到SRF持续吸收。12 个月时，持续组的 BCVA 从 0.39 ± 0.18 显著改善到 0.19 ± 0.2 logMAR（P = 0.01），中央眼底厚度（CST）从 316.44 ± 75.83 mm 减少到 197.结论PDT为成功治疗对SML治疗无反应的CSCR提供了机会。即使是症状持续时间较长、视网膜形态发生显著改变的病例，也有可能获得改善。因此，脉络膜厚度明显增加的患者应考虑使用 PDT。

{"title":"Crossover to PDT after the unsuccessful micropulse laser treatment of central serous chorioretinopathy","authors":"Maciej Gawęcki , Krzysztof Kiciński , Andrzej Grzybowski","doi":"10.1016/j.aopr.2024.01.004","DOIUrl":"10.1016/j.aopr.2024.01.004","url":null,"abstract":"<div><h3>Purpose</h3><p>Subthreshold micropulse laser (SML) and photodynamic therapy (PDT) are among the most effective therapeutic modalities applied to central serous chorioretinopathy (CSCR). This study aimed to evaluate the efficacy and durability of PDT in CSCR cases unresponsive to at least two SML treatments.</p></div><div><h3>Methods</h3><p>The study included 26 consecutive eyes of 24 patients (21 males and three females) with chronic CSCR. In all cases, a lack of reduction in subretinal fluid (SRF) levels was noted after at least two consecutive SML sessions. The parameters of best corrected visual acuity (BCVA) and spectral domain optical coherence tomography (SD-OCT) were evaluated at baseline and 1, 3 and 12 months post-PDT.</p></div><div><h3>Results</h3><p>The mean duration of symptoms in the group was 53.81 ± 39.48 months, the mean age of the patients was 49.26 ± 12.91 years, and the mean subfoveal choroidal thickness (SFCT) was 572.11 ± 116.21 mm. Complete resorption of SRF was observed in 21 out of 26 eyes (80.77%) at 1 month and sustained in 18 cases (69.23%) at 12 months. At 12 months, in the sustained group, BCVA improved significantly from 0.39 ± 0.18 to 0.19 ± 0.2 logMAR (<em>P</em> = 0.01), central subfoveal thickness (CST) reduced from 316.44 ± 75.83 mm to 197.67 ± 22.99 mm (<em>P</em> < 0.0001), and SFCT reduced from 579.28 mm to 446.78 mm (<em>P</em> < 0.0001).</p></div><div><h3>Conclusions</h3><p>PDT provides the opportunity for the successful treatment of CSCR unresponsive to SML treatment. Improvements are possible even in cases with a long duration of symptoms and significant alterations in retinal morphology. Thus, PDT should be considered for patients with prominently increased choroidal thickness.</p></div>","PeriodicalId":72103,"journal":{"name":"Advances in ophthalmology practice and research","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667376224000040/pdfft?md5=d6e2139d9e4970a2e57c228e7f858403&pid=1-s2.0-S2667376224000040-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139631916","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evaluating for unrecognized deficits in perimetry associated with functional upper eyelid malposition 评估与功能性上眼睑位置不正有关的未识别的视力缺陷

Advances in ophthalmology practice and research

Pub Date : 2024-02-01 DOI: 10.1016/j.aopr.2024.01.007

Linyan Wang, Davin C. Ashraf, Michael Deiner, Oluwatobi O. Idowu, Seanna R. Grob, Bryan J. Winn, M. Vagefi, Robert C. Kersten

引用次数: 0

An assessment of the capability of ChatGPT in solving clinical cases of ophthalmology using multiple choice and short answer questions 评估 ChatGPT 使用选择题和简答题解决眼科临床病例的能力

Advances in ophthalmology practice and research

Pub Date : 2024-01-19 DOI: 10.1016/j.aopr.2024.01.005

Anjana Christy Alexander , Suprithy Somineni Raghupathy , Krishna Mohan Surapaneni

引用次数: 0

Is relying on RNFL specific enough to identify any changes in the CNS? 依靠 RNFL 的特异性是否足以识别中枢神经系统的任何变化？

Advances in ophthalmology practice and research

Pub Date : 2024-01-17 DOI: 10.1016/j.aopr.2024.01.002

Dzakky Avecienna Nur Faridwazdi, Yuliono Trika Nur Hasan, Alvi Milliana, Zulvikar Syambani Ulhaq

引用次数: 0

Evaluation of choroidal thickness and retinal nerve fiber layer thickness in Chinese pregnant women and healthy non-pregnant women 评估中国孕妇和健康非孕妇的脉络膜厚度和视网膜神经纤维层厚度

Advances in ophthalmology practice and research

Pub Date : 2023-12-06 DOI: 10.1016/j.aopr.2023.12.001

Hanfei Wu , Haishuang Lin , Mengting Ruan , Huanjie Fang , Nannan Dong , Tiewei Wang , Feifei Yu , Jiawei Zhao

Purpose

To evaluate choroidal thickness and retinal nerve fiber layer (RNFL) thickness in different trimesters using enhanced depth imaging optical coherence tomography (EDI-OCT).

Methods

A prospective comparative study included 45 healthy pregnant women in the first trimester, 45 women in the second, 45 women in the third and 45 healthy non-pregnant women as the control group. Macular choroidal thickness was measured at three locations: The subfoveal, 1 mm temporal, and 1 mm nasal from the fovea with EDI-OCT. Peripapillary choroidal thickness (PPCT) and RNFL thickness parameters were automatically calculated by the Spectralis OCT.

Results

The subfoveal, temporal and nasal macular choroidal thickness were all significantly thicker in the second trimester, compared with those parameters in the first, the third trimesters and the control group (all P < 0.05). The PPCT was significantly increased in the second trimeter compared with the control group at global, temporal, temporal inferior, nasal and nasal inferior positions (all P < 0.05). The RNFL thickness was also significantly increased in pregnant women at nasal superior and nasal inferior quadrants (all P < 0.05).

Conclusions

The choroidal thickness in pregnant women was found to be thicker than the control group, regardless of macular or optic disc location. Findings of RNFL thickening might indicate subclinical involvement of the central nervous system.

目的使用增强型深度成像光学相干断层扫描（EDI-OCT）评估不同孕期的脉络膜厚度和视网膜神经纤维层（RNFL）厚度。方法一项前瞻性比较研究纳入了 45 名健康孕妇，包括孕期前三个月的孕妇、孕期后三个月的孕妇、孕期前三个月的孕妇以及作为对照组的 45 名健康非孕妇。在三个位置测量黄斑脉络膜厚度：使用 EDI-OCT 在三个位置测量黄斑脉络膜厚度：眼窝下、距离眼窝 1 毫米的颞侧和 1 毫米的鼻侧。结果与妊娠头三个月、妊娠三个月和对照组相比，妊娠后三个月的眼底、颞侧和鼻侧黄斑脉络膜厚度均明显增厚（均为 P <0.05）。与对照组相比，妊娠中期的 PPCT 在全球、颞、颞下、鼻和鼻下位置均明显增加（均为 P < 0.05）。结论无论黄斑或视盘位置如何，孕妇的脉络膜厚度都比对照组厚。RNFL增厚的发现可能表明中枢神经系统受到亚临床影响。

{"title":"Evaluation of choroidal thickness and retinal nerve fiber layer thickness in Chinese pregnant women and healthy non-pregnant women","authors":"Hanfei Wu , Haishuang Lin , Mengting Ruan , Huanjie Fang , Nannan Dong , Tiewei Wang , Feifei Yu , Jiawei Zhao","doi":"10.1016/j.aopr.2023.12.001","DOIUrl":"10.1016/j.aopr.2023.12.001","url":null,"abstract":"<div><h3>Purpose</h3><p>To evaluate choroidal thickness and retinal nerve fiber layer (RNFL) thickness in different trimesters using enhanced depth imaging optical coherence tomography (EDI-OCT).</p></div><div><h3>Methods</h3><p>A prospective comparative study included 45 healthy pregnant women in the first trimester, 45 women in the second, 45 women in the third and 45 healthy non-pregnant women as the control group. Macular choroidal thickness was measured at three locations: The subfoveal, 1 mm temporal, and 1 mm nasal from the fovea with EDI-OCT. Peripapillary choroidal thickness (PPCT) and RNFL thickness parameters were automatically calculated by the Spectralis OCT.</p></div><div><h3>Results</h3><p>The subfoveal, temporal and nasal macular choroidal thickness were all significantly thicker in the second trimester, compared with those parameters in the first, the third trimesters and the control group (all <em>P</em> < 0.05). The PPCT was significantly increased in the second trimeter compared with the control group at global, temporal, temporal inferior, nasal and nasal inferior positions (all <em>P</em> < 0.05). The RNFL thickness was also significantly increased in pregnant women at nasal superior and nasal inferior quadrants (all <em>P</em> < 0.05).</p></div><div><h3>Conclusions</h3><p>The choroidal thickness in pregnant women was found to be thicker than the control group, regardless of macular or optic disc location. Findings of RNFL thickening might indicate subclinical involvement of the central nervous system.</p></div>","PeriodicalId":72103,"journal":{"name":"Advances in ophthalmology practice and research","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-12-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667376223000628/pdfft?md5=e1acd14582585864316213ce1a25fe6e&pid=1-s2.0-S2667376223000628-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138625448","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Global research on artificial intelligence in thyroid-associated ophthalmopathy: A bibliometric analysis 全球甲状腺相关眼病人工智能研究：文献计量分析

Advances in ophthalmology practice and research

Pub Date : 2023-11-30 DOI: 10.1016/j.aopr.2023.11.002

Xiaobin Zhang

Purpose

To provide an overview of global publications on artificial intelligence (AI) in thyroid-associated ophthalmopathy (TAO) through bibliometric analysis.

Methods

Publications related to AI in TAO from inception until April 2023 were retrieved from the Web of Science database. The trends of publications and citations, publishing performance, collaboration among countries and institutions, and the funding agencies, relevant research domains, leading journals, hotspots and their evolution were identified.

Results

A total of 55 publications were included for analysis. The number of publications and citations continued to grow since 1998, with a significant acceleration of growth after 2020. China is the most productive country with the highest number of productive institutions, followed by the United States. European countries have the most extensive collaboration. The most relevant research domain was radiology, nuclear medicine & medical imaging. The European Journal of Radiology was one of the most productive journals, with the most influential articles published. "Thyroid-associated ophthalmopathy" and "neural network" maintain hotspots during the entire period. Studies were more focused on clinical features during 1998 and 2016, clinical features and medical data during 2017 and 2020, and medical data and AI techniques during 2021 and 2023.

Conclusions

This study summarized the global research status regarding AI in TAO in terms of trends, countries, institutions, research domains, journals, and key topics. AI has shown great potential in TAO. Sponsored by funding agencies such as NSFC, China has become the most productive country in the field of AI in TAO. Our findings help researchers better understand the development of this field and provide valuable clues for future research directions.

目的通过文献计量学分析，概述人工智能（AI）在甲状腺相关性眼病（TAO）中的全球发表情况。方法从Web of Science数据库中检索了从开始到2023年4月与人工智能在TAO中的应用相关的出版物。结果共纳入 55 篇论文进行分析。自 1998 年以来，论文数量和引用次数持续增长，2020 年后增长速度明显加快。中国是成果最多的国家，拥有最多的成果机构，其次是美国。欧洲国家的合作最为广泛。最相关的研究领域是放射学、核医学和医学成像。欧洲放射学杂志》是成果最多的杂志之一，发表的文章最具影响力。"甲状腺相关性眼病 "和 "神经网络 "是整个研究期间的热点。1998年和2016年的研究更关注临床特征，2017年和2020年的研究更关注临床特征和医学数据，2021年和2023年的研究更关注医学数据和人工智能技术。结论本研究从趋势、国家、机构、研究领域、期刊和关键主题等方面总结了全球人工智能在TAO领域的研究现状。人工智能在医疗卫生领域显示出巨大潜力。在国家自然科学基金委等资助机构的赞助下，中国已成为人工智能在航空航天领域最有成效的国家。我们的研究结果有助于研究人员更好地了解这一领域的发展，并为未来的研究方向提供有价值的线索。

{"title":"Global research on artificial intelligence in thyroid-associated ophthalmopathy: A bibliometric analysis","authors":"Xiaobin Zhang","doi":"10.1016/j.aopr.2023.11.002","DOIUrl":"https://doi.org/10.1016/j.aopr.2023.11.002","url":null,"abstract":"<div><h3>Purpose</h3><p>To provide an overview of global publications on artificial intelligence (AI) in thyroid-associated ophthalmopathy (TAO) through bibliometric analysis.</p></div><div><h3>Methods</h3><p>Publications related to AI in TAO from inception until April 2023 were retrieved from the Web of Science database. The trends of publications and citations, publishing performance, collaboration among countries and institutions, and the funding agencies, relevant research domains, leading journals, hotspots and their evolution were identified.</p></div><div><h3>Results</h3><p>A total of 55 publications were included for analysis. The number of publications and citations continued to grow since 1998, with a significant acceleration of growth after 2020. China is the most productive country with the highest number of productive institutions, followed by the United States. European countries have the most extensive collaboration. The most relevant research domain was radiology, nuclear medicine & medical imaging. The European Journal of Radiology was one of the most productive journals, with the most influential articles published. \"Thyroid-associated ophthalmopathy\" and \"neural network\" maintain hotspots during the entire period. Studies were more focused on clinical features during 1998 and 2016, clinical features and medical data during 2017 and 2020, and medical data and AI techniques during 2021 and 2023.</p></div><div><h3>Conclusions</h3><p>This study summarized the global research status regarding AI in TAO in terms of trends, countries, institutions, research domains, journals, and key topics. AI has shown great potential in TAO. Sponsored by funding agencies such as <span>NSFC</span>, China has become the most productive country in the field of AI in TAO. Our findings help researchers better understand the development of this field and provide valuable clues for future research directions.</p></div>","PeriodicalId":72103,"journal":{"name":"Advances in ophthalmology practice and research","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667376223000616/pdfft?md5=b0657727e2896bf0f24203eb5942eb1d&pid=1-s2.0-S2667376223000616-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138839597","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Search of inhibitors of aldose reductase for treatment of diabetic cataracts using machine learning 利用机器学习寻找醛糖还原酶抑制剂治疗糖尿病性白内障。

Advances in ophthalmology practice and research

Pub Date : 2023-11-01 DOI: 10.1016/j.aopr.2023.09.002

Trevor Chen , Richard Chen , Alvin You , Valentina L. Kouznetsova , Igor F. Tsigelny

Purpose

Patients with diabetes mellitus have an elevated chance of developing cataracts, a degenerative vision-impairing condition often needing surgery. The process of the reduction of glucose to sorbitol in the lens of the human eye that causes cataracts is managed by the Aldose Reductase Enzyme (AR), and it is been found that AR inhibitors may mitigate the onset of diabetic cataracts. There exists a large pool of natural and synthetic AR inhibitors that can prevent diabetic complications, and the development of a machine-learning (ML) prediction model may bring new AR inhibitors with better characteristics into clinical use.

Methods

Using known AR inhibitors and their chemical-physical descriptors we created the ML model for prediction of new AR inhibitors. The predicted inhibitors were tested by computational docking to the binding site of AR.

Results

Using cross-validation in order to find the most accurate ML model, we ended with final cross-validation accuracy of 90%. Computational docking testing of the predicted inhibitors gave a high level of correlation between the ML prediction score and binding free energy.

Conclusions

Currently known AR inhibitors are not used yet for patients for several reasons. We think that new predicted AR inhibitors have the potential to possess more favorable characteristics to be successfully implemented after clinical testing. Exploring new inhibitors can improve patient well-being and lower surgical complications all while decreasing long-term medical expenses.

目的：糖尿病患者患白内障的几率较高，白内障是一种退行性视力受损的疾病，通常需要手术治疗。导致白内障的人眼晶状体中葡萄糖还原为山梨醇的过程由醛糖还原酶（AR）控制，已经发现AR抑制剂可以减轻糖尿病性白内障的发作。存在大量可以预防糖尿病并发症的天然和合成AR抑制剂，机器学习（ML）预测模型的开发可能会使具有更好特性的新型AR抑制剂投入临床使用。方法：使用已知的AR抑制剂及其化学-物理描述符，我们创建了预测新AR抑制剂的ML模型。预测的抑制剂通过与AR结合位点的计算对接进行了测试。结果：使用交叉验证，为了找到最准确的ML模型，我们最终的交叉验证准确率为90%。预测抑制剂的计算对接测试给出了ML预测分数和结合自由能之间的高度相关性。结论：由于多种原因，目前已知的AR抑制剂尚未用于患者。我们认为，新的预测AR抑制剂有可能具有更有利的特性，在临床测试后成功实施。探索新的抑制剂可以改善患者的健康状况，降低手术并发症，同时减少长期医疗费用。

{"title":"Search of inhibitors of aldose reductase for treatment of diabetic cataracts using machine learning","authors":"Trevor Chen , Richard Chen , Alvin You , Valentina L. Kouznetsova , Igor F. Tsigelny","doi":"10.1016/j.aopr.2023.09.002","DOIUrl":"10.1016/j.aopr.2023.09.002","url":null,"abstract":"<div><h3>Purpose</h3><p>Patients with diabetes mellitus have an elevated chance of developing cataracts, a degenerative vision-impairing condition often needing surgery. The process of the reduction of glucose to sorbitol in the lens of the human eye that causes cataracts is managed by the Aldose Reductase Enzyme (AR), and it is been found that AR inhibitors may mitigate the onset of diabetic cataracts. There exists a large pool of natural and synthetic AR inhibitors that can prevent diabetic complications, and the development of a machine-learning (ML) prediction model may bring new AR inhibitors with better characteristics into clinical use.</p></div><div><h3>Methods</h3><p>Using known AR inhibitors and their chemical-physical descriptors we created the ML model for prediction of new AR inhibitors. The predicted inhibitors were tested by computational docking to the binding site of AR.</p></div><div><h3>Results</h3><p>Using cross-validation in order to find the most accurate ML model, we ended with final cross-validation accuracy of 90%. Computational docking testing of the predicted inhibitors gave a high level of correlation between the ML prediction score and binding free energy.</p></div><div><h3>Conclusions</h3><p>Currently known AR inhibitors are not used yet for patients for several reasons. We think that new predicted AR inhibitors have the potential to possess more favorable characteristics to be successfully implemented after clinical testing. Exploring new inhibitors can improve patient well-being and lower surgical complications all while decreasing long-term medical expenses.</p></div>","PeriodicalId":72103,"journal":{"name":"Advances in ophthalmology practice and research","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10624573/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71489518","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

TOC 技术选择委员会

Advances in ophthalmology practice and research

Pub Date : 2023-11-01 DOI: 10.1016/S2667-3762(23)00057-4

引用次数: 0

首页上一页

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

Advances in ophthalmology practice and research

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀